Natural Product (NP) Details
| General Information of the NP (ID: NP0649) | |||||
|---|---|---|---|---|---|
| Name |
Ellagic acid
|
||||
| Synonyms |
Benzoaric acid; Lagistase; Eleagic acid; Alizarine Yellow; Elagostasine; 2,3,7,8-Tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione; Ellagic acid dihydrate; Llagic acid; Acide ellagique; Acido elagico; Acidum ellagicum; C.I. 55005; Gallogen (VAN); Gallogen (astringent); C.I. 75270; Ellagate; Ellagic acid [INN:DCF]; UNII-19YRN3ZS9P; Acido elagico [INN-Spanish]; CCRIS 774; Gallogen, astringent; Acide ellagique [INN-French]; Acidum ellagicum [INN-Latin]; MLS000069632; C14H6O8; EINECS 207-508-3; NSC407286; NSC 40728
Click to Show/Hide
|
||||
| Species Origin | Lagerstroemia speciosa ... | Click to Show/Hide | |||
| Lagerstroemia speciosa | |||||
| Toxicodendron succedaneum | |||||
| Rhus chinensis | |||||
| Triadica cochinchinensis | |||||
| Disease | Rheumatoid arthritis [ICD-11: FA20] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.167
MDCK Permeability
-4.743
PAMPA
+++
HIA
-
Distribution
VDss
-0.353
PPB
68.5%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
+
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
-
HLM Stability
-
Excretion
CLplasma
14.743
T1/2
1.648
Toxicity
DILI
+++
Rat Oral Acute Toxicity
+
FDAMDD
+
Respiratory
- -
Human Hepatotoxicity
+
Ototoxicity
-
Drug-induced Nephrotoxicity
- - -
Drug-induced Neurotoxicity
- - -
Hematotoxicity
- -
Genotoxicity
+++
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C14H6O8
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=C2C3=C(C(=C1O)O)OC(=O)C4=CC(=C(C(=C43)OC2=O)O)O
|
||||
| InChI |
1S/C14H6O8/c15-5-1-3-7-8-4(14(20)22-11(7)9(5)17)2-6(16)10(18)12(8)21-13(3)19/h1-2,15-18H
|
||||
| InChIKey |
AFSDNFLWKVMVRB-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 476-66-4
|
||||
| Herb ID | |||||
| ETMC ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | ||
| Experimental
Result(s) |
Combining ellagic acid with temozolomide mediates the cadherin switch and angiogenesis in a glioblastoma model. | |||||
| Bevacizumab | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | MGMT | Molecule Info | |||
| Up-regulation | Expression | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | C6 | CVCL_0194 | Rat malignant glioma | Rattus norvegicus | ||
| Experimental
Result(s) |
Antiproliferative efficacy of EA combined with BEV, probably through inhibition of MGMT expression and time-dependent inhibition of MDR1. | |||||
| Sorafenib | Renal cell carcinoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| Up-regulation | Cytochrome c release | |||||
| In-vivo Model | Dietylnitrosamine and 2-acetylami nofluorene were used to induce HCC in male Sprague-Dawley rats. | |||||
| Experimental
Result(s) |
EA and SOR are effective on the HCC rat model through mitochondria and hepatocytes targeting. | |||||
| 5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [5] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
| COLO 320DM | CVCL_0219 | Colon adenocarcinoma | Homo sapiens | |||
| SW480 | CVCL_0546 | Colon adenocarcinoma | Homo sapiens | |||
| LoVo | CVCL_0399 | Colon adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Ellagic acid synergistically potentiated chemosensitivity to 5-fluorouracil in colorectal cancer cells. | |||||
| Erlotinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [6] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Ba/F3 | CVCL_0161 | Healthy | Mus musculus | ||
| WEHI-265.1 | CVCL_3620 | Mouse leukemia | Mus musculus | |||
| In-vivo Model | Ba/F3-insH cell line xenografts were generated by injecting 5*106 cells in 50% matrigel into six-to eight- week old male nu/nu nude mice. | |||||
| Experimental
Result(s) |
The combination of ellagic acid with erlotinib has synergistic effects against EGFR H773_V774 insH mutation. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase (CA) | Molecule Info | [7] | |
| Casein kinase II alpha (CSNK2A1) | Molecule Info | [8] | ||
| Glycogen synthase kinase-3 beta (GSK-3B) | Molecule Info | [9] | ||
| Heat shock protein 70 (HSP70) | Molecule Info | [10] | ||
| Mothers against decapentaplegic 3 (SMAD3) | Molecule Info | [10] | ||
| Squalene monooxygenase (SQLE) | Molecule Info | [11] | ||
| Tyrosine-protein kinase SYK (SYK) | Molecule Info | [9] | ||
| KEGG Pathway | ErbB signaling pathway | Click to Show/Hide | ||
| 2 | Chemokine signaling pathway | |||
| 3 | Cell cycle | |||
| 4 | PI3K-Akt signaling pathway | |||
| 5 | Wnt signaling pathway | |||
| 6 | Hedgehog signaling pathway | |||
| 7 | Axon guidance | |||
| 8 | Hippo signaling pathway | |||
| 9 | Focal adhesion | |||
| 10 | Signaling pathways regulating pluripotency of stem cells | |||
| 11 | T cell receptor signaling pathway | |||
| 12 | B cell receptor signaling pathway | |||
| 13 | Neurotrophin signaling pathway | |||
| 14 | Dopaminergic synapse | |||
| 15 | Insulin signaling pathway | |||
| 16 | Melanogenesis | |||
| 17 | Prolactin signaling pathway | |||
| 18 | Thyroid hormone signaling pathway | |||
| 19 | Non-alcoholic fatty liver disease (NAFLD) | |||
| 20 | Alzheimer's disease | |||
| 21 | Hepatitis C | |||
| 22 | Measles | |||
| 23 | Influenza A | |||
| 24 | HTLV-I infection | |||
| 25 | Epstein-Barr virus infection | |||
| 26 | Pathways in cancer | |||
| 27 | Colorectal cancer | |||
| 28 | Endometrial cancer | |||
| 29 | Prostate cancer | |||
| 30 | Basal cell carcinoma | |||
| 31 | Ribosome biogenesis in eukaryotes | |||
| 32 | NF-kappa B signaling pathway | |||
| 33 | Adherens junction | |||
| 34 | Tight junction | |||
| 35 | Herpes simplex infection | |||
| 36 | Steroid biosynthesis | |||
| 37 | Sesquiterpenoid and triterpenoid biosynthesis | |||
| 38 | Metabolic pathways | |||
| 39 | Biosynthesis of secondary metabolites | |||
| 40 | Biosynthesis of antibiotics | |||
| 41 | Osteoclast differentiation | |||
| 42 | Platelet activation | |||
| 43 | Natural killer cell mediated cytotoxicity | |||
| 44 | Fc epsilon RI signaling pathway | |||
| 45 | Fc gamma R-mediated phagocytosis | |||
| 46 | Tuberculosis | |||
| 47 | Viral carcinogenesis | |||
| NetPath Pathway | FSH Signaling Pathway | Click to Show/Hide | ||
| Panther Pathway | Alzheimer disease-presenilin pathway | Click to Show/Hide | ||
| 2 | Angiogenesis | |||
| 3 | Cadherin signaling pathway | |||
| 4 | Hedgehog signaling pathway | |||
| 5 | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 6 | Insulin/IGF pathway-protein kinase B signaling cascade | |||
| 7 | Interleukin signaling pathway | |||
| 8 | PDGF signaling pathway | |||
| 9 | PI3 kinase pathway | |||
| 10 | Wnt signaling pathway | |||
| 11 | Ras Pathway | |||
| 12 | CCKR signaling map ST | |||
| 13 | B cell activation | |||
| Pathwhiz Pathway | Steroid Biosynthesis | Click to Show/Hide | ||
| 2 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
| Pathway Interaction Database | LPA receptor mediated events | Click to Show/Hide | ||
| 2 | Degradation of beta catenin | |||
| 3 | Reelin signaling pathway | |||
| 4 | Presenilin action in Notch and Wnt signaling | |||
| 5 | Integrin-linked kinase signaling | |||
| 6 | CDC42 signaling events | |||
| 7 | LKB1 signaling events | |||
| 8 | Canonical Wnt signaling pathway | |||
| 9 | Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||
| 10 | Glucocorticoid receptor regulatory network | |||
| 11 | C-MYC pathway | |||
| 12 | Regulation of Androgen receptor activity | |||
| 13 | BMP receptor signaling | |||
| 14 | Hedgehog signaling events mediated by Gli proteins | |||
| 15 | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| 16 | Validated transcriptional targets of deltaNp63 isoforms | |||
| 17 | Aurora A signaling | |||
| 18 | Insulin-mediated glucose transport | |||
| 19 | Class I PI3K signaling events mediated by Akt | |||
| 20 | p53 pathway | |||
| 21 | Trk receptor signaling mediated by PI3K and PLC-gamma | |||
| 22 | BCR signaling pathway | |||
| 23 | Atypical NF-kappaB pathway | |||
| 24 | DNA-PK pathway in nonhomologous end joining | |||
| 25 | E-cadherin signaling in the nascent adherens junction | |||
| 26 | Lissencephaly gene (LIS1) in neuronal migration and development | |||
| 27 | PDGFR-alpha signaling pathway | |||
| 28 | Signaling mediated by p38-alpha and p38-beta | |||
| 29 | Alpha-synuclein signaling | |||
| 30 | Fc-epsilon receptor I signaling in mast cells | |||
| 31 | GMCSF-mediated signaling events | |||
| 32 | Osteopontin-mediated events | |||
| 33 | FAS (CD95) signaling pathway | |||
| 34 | Thromboxane A2 receptor signaling | |||
| 35 | IL2-mediated signaling events | |||
| 36 | Class I PI3K signaling events | |||
| Reactome | Degradation of beta-catenin by the destruction complex | Click to Show/Hide | ||
| 2 | AKT phosphorylates targets in the cytosol | |||
| 3 | Regulation of HSF1-mediated heat shock response | |||
| 4 | CRMPs in Sema3A signaling | |||
| 5 | Disassembly of the destruction complex and recruitment of AXIN to the membrane | |||
| 6 | S33 mutants of beta-catenin aren't phosphorylated | |||
| 7 | S37 mutants of beta-catenin aren't phosphorylated | |||
| 8 | S45 mutants of beta-catenin aren't phosphorylated | |||
| 9 | T41 mutants of beta-catenin aren't phosphorylated | |||
| 10 | Degradation of GLI2 by the proteasome | |||
| 11 | Constitutive Signaling by AKT1 E17K in Cancer | |||
| 12 | Condensation of Prometaphase Chromosomes | |||
| 13 | Cholesterol biosynthesis | |||
| 14 | Activation of gene expression by SREBF (SREBP) | |||
| 15 | GPVI-mediated activation cascade | |||
| 16 | FCGR activation | |||
| 17 | Regulation of actin dynamics for phagocytic cup formation | |||
| 18 | Role of phospholipids in phagocytosis | |||
| 19 | DAP12 signaling | |||
| 20 | Fc epsilon receptor (FCERI) signaling | |||
| 21 | Role of LAT2/NTAL/LAB on calcium mobilization | |||
| 22 | FCERI mediated MAPK activation | |||
| 23 | FCERI mediated Ca+2 mobilization | |||
| 24 | Integrin alphaIIb beta3 signaling | |||
| 25 | Interleukin-2 signaling | |||
| 26 | CLEC7A (Dectin-1) signaling | |||
| 27 | Dectin-2 family | |||
| 28 | Regulation of signaling by CBL | |||
| 29 | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||
| WikiPathways | DNA Damage Response (only ATM dependent) | Click to Show/Hide | ||
| 2 | Senescence and Autophagy in Cancer | |||
| 3 | Notch Signaling Pathway | |||
| 4 | Glycogen Metabolism | |||
| 5 | Insulin Signaling | |||
| 6 | Wnt Signaling Pathway | |||
| 7 | Wnt Signaling Pathway and Pluripotency | |||
| 8 | IL-6 signaling pathway | |||
| 9 | Wnt Signaling Pathway Netpath | |||
| 10 | Copper homeostasis | |||
| 11 | Focal Adhesion | |||
| 12 | Hair Follicle Development: Induction (Part 1 of 3) | |||
| 13 | Cardiac Hypertrophic Response | |||
| 14 | Degradation of beta-catenin by the destruction complex | |||
| 15 | T-Cell Receptor and Co-stimulatory Signaling | |||
| 16 | Cardiac Progenitor Differentiation | |||
| 17 | BDNF signaling pathway | |||
| 18 | Corticotropin-releasing hormone | |||
| 19 | B Cell Receptor Signaling Pathway | |||
| 20 | IL17 signaling pathway | |||
| 21 | Neural Crest Differentiation | |||
| 22 | Alzheimers Disease | |||
| 23 | IL-7 Signaling Pathway | |||
| 24 | Regulation of Microtubule Cytoskeleton | |||
| 25 | TWEAK Signaling Pathway | |||
| 26 | Leptin signaling pathway | |||
| 27 | Semaphorin interactions | |||
| 28 | Cell Cycle | |||
| 29 | MicroRNAs in cardiomyocyte hypertrophy | |||
| 30 | Androgen receptor signaling pathway | |||
| 31 | IL-5 Signaling Pathway | |||
| 32 | Mitotic Prometaphase | |||
| 33 | TNF alpha Signaling Pathway | |||
| 34 | L1CAM interactions | |||
| 35 | IL-2 Signaling Pathway | |||
| 36 | IL-3 Signaling Pathway | |||
| 37 | Fc epsilon receptor (FCERI) signaling | |||
| 38 | Signaling by the B Cell Receptor (BCR) | |||
| 39 | Interleukin-2 signaling | |||
| 40 | Fcgamma receptor (FCGR) dependent phagocytosis | |||
| 41 | DAP12 interactions | |||
| 42 | RANKL/RANK Signaling Pathway | |||
| 43 | Integrin alphaIIb beta3 signaling | |||
| 44 | GPVI-mediated activation cascade | |||
| 45 | Regulation of toll-like receptor signaling pathway | |||